Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Korro Bio, Inc. (KRRO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on Nasdaq. Korro focuses on RNA-editing genetic medicines, and its filings with the U.S. Securities and Exchange Commission offer detailed information on clinical programs, collaborations, restructuring actions, and executive changes that complement its press releases.
Investors can review Forms 10-K and 10-Q for narrative and financial discussion of Korro’s development of KRRO-110 for Alpha-1 Antitrypsin Deficiency, the REWRITE Phase 1/2a clinical trial design, and the OPERA RNA editing platform. These periodic reports also describe risk factors, research and development spending, and collaboration revenue, including from its research collaboration and license agreement with Novo Nordisk A/S.
Current reports on Form 8-K are particularly relevant for tracking material events at Korro. Recent 8-K filings describe the amendment to the Novo Nordisk collaboration establishing a 12‑month pause in research and development activities, strategic restructuring and workforce reductions intended to extend cash runway, and executive transitions such as the resignation of the Chief Financial Officer and Chief Medical Officer and related separation agreements. Other 8-Ks outline compensatory arrangements, including amended employment agreements and equity awards.
Users can also monitor proxy statements and compensation disclosures referenced in Korro’s 8-Ks for background on executive employment terms, as well as any Form 4 insider transaction reports that may be filed to reflect equity grants or option exercises under the company’s stock plans. Stock Titan enhances these filings with AI-powered summaries that explain key points in accessible language, highlight important sections of long reports, and help readers quickly understand how new filings may relate to Korro’s RNA-editing pipeline, collaborations, and capital allocation.
Point72-affiliated entities filed an amended Schedule 13G reporting a 2.9% passive stake in Korro Bio, Inc. common stock. As of the close of business on December 31, 2025, Point72 Biotech Private Investments, LLC, Differentiated Ventures Investments, LLC, 72 Investment Holdings, LLC and Steven A. Cohen are each reported as beneficial owners of 276,831 shares of Korro Bio common stock, representing 2.9% of the outstanding class. Point72 Asset Management, L.P. and Point72 Capital Advisors, Inc. report no direct holdings, though the filing describes their roles in managing and controlling affiliated entities. The signatories certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Korro Bio.
Driehaus Capital Management LLC has amended its ownership report for Korro Bio, Inc., stating that it now beneficially owns 0 shares of Korro Bio common stock, representing 0% of the class as of 12/31/2025. The filer confirms it holds no sole or shared voting or dispositive power over any Korro Bio shares and notes this is an exit filing indicating ownership of 5 percent or less of the company’s common stock.
Nantahala Capital Management, LLC and its principals reported a significant ownership stake in Korro Bio, Inc. As of December 31, 2025, they may be deemed to beneficially own 600,000 shares of Korro Bio common stock, representing 6.37% of the outstanding shares.
The shares are held by funds and separately managed accounts under Nantahala’s control, with Nantahala, Wilmot B. Harkey, and Daniel Mack sharing voting and dispositive power over all 600,000 shares. They state that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Korro Bio.
FMR LLCAbigail P. Johnson report beneficial ownership of 37,857 shares of Korro Bio Inc. common stock, representing 0.4% of the outstanding class as of the event date of December 31, 2025.
FMR LLC has sole voting power over 33,257 shares and sole dispositive power over 37,857 shares. Abigail P. Johnson reports sole dispositive power over the same 37,857 shares, with no voting power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Korro Bio. One or more other persons may receive dividends or sale proceeds from these shares, but no such person holds more than five percent of the common stock.
Korro Bio, Inc. reported that President and CEO Ram Aiyar received new equity awards on February 2, 2026. He was granted 40,000 shares of common stock through restricted stock units under the 2023 Stock Option and Incentive Plan, vesting 50% on August 3, 2026 and 50% on February 1, 2027, subject to continued service.
He was also granted a stock option for 80,000 shares of common stock at an exercise price of $13.05, vesting in 48 equal monthly installments starting February 2, 2026 and expiring February 1, 2036. Separately, 4,613 common shares are held indirectly by The Ram Aiyar Irrevocable Trust, for which he serves as trustee and disclaims full beneficial ownership.
Korro Bio, Inc. reported that its Chief Scientific Officer, Vincent Loic A, received a grant of stock options on February 2, 2026. The award covers 35,000 stock options with an exercise price of $13.05 per share for Korro Bio common stock.
The options vest in 48 equal monthly installments starting on February 2, 2026, and each monthly vesting is conditioned on the executive’s continued service on that date. After this grant, the officer beneficially owns 35,000 derivative securities directly.
Korro Bio, Inc. reported that Senior Vice President of Finance Dolan Oliver received a stock option award. On February 2, 2026, Oliver was granted an option to buy 15,000 shares of Korro Bio common stock at an exercise price of $13.05 per share, expiring February 1, 2036.
The option vests in 48 equal monthly installments starting February 2, 2026, contingent on Oliver’s continued service with the company on each vesting date. After this grant, Oliver beneficially owns 15,000 derivative securities directly.
Korro Bio, Inc. reported that its General Counsel, Jeffrey Cerio, received a grant of stock options covering 23,000 shares of common stock. The options have an exercise price of $13.05 per share and were awarded on February 2, 2026.
These options vest in 48 equal monthly installments starting on February 2, 2026, and each vesting date requires Mr. Cerio to remain in service with the company. Following this grant, he beneficially holds options for 23,000 shares, all in direct ownership.
Korro Bio, Inc. reported that Chief Operating Officer Todd Chappell received a stock option award for 38,000 derivative securities described as a stock option (right to buy) common stock. The option has an exercise price of $13.05 per share and was granted on February 2, 2026.
The grant was made for no purchase price and leaves Chappell with 38,000 stock options beneficially owned directly. These options expire on February 1, 2036 and vest in 48 equal monthly installments starting February 2, 2026, conditioned on his continued service at each vesting date.
The Vanguard Group has filed a Schedule 13G reporting a passive ownership stake in Korro Bio Inc. Vanguard reports beneficial ownership of 489,639 shares of Korro Bio common stock, representing 5.19% of the class as of the event date.
Vanguard lists shared voting power over 43,589 shares and shared dispositive power over 489,639 shares, with no sole voting or dispositive power. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Korro Bio.